Follow-up investment in Xeltis for market introduction of groundbreaking vascular prosthesis

Natural tissue regeneration

Xeltis is developing a unique technology: an implant that stimulates the body to form new living tissue. Xeltis is developing this technology for multiple cardiovascular applications, including in a vascular prosthesis for hemodialysis patients: aXess. Traditional forms of vascular access often fail and cause complications. With aXess, Xeltis aims to significantly improve the quality of care and the quality of life for these patients. 

Invest-NL already invested € 6 million in Xeltis in 2023 to further develop this promising technology. A recent clinical study showed exceptionally positive results: high durability, fewer infections, and fewer interventions than current standard care.

Final step towards commercialization

With this funding, Xeltis can take the final step towards commercialization: scaling up production, expanding the team, and preparing for market approval in Europe and the United States. European market approval is expected in 2026.

“aXess is on the verge of market introduction and could fundamentally improve the standard care for dialysis patients. This is exactly the type of innovation Invest-NL stands for: groundbreaking, scalable, and with a significant societal impact,” says Mats Wassink, investment associate at Invest-NL.